Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia

NCT01328236 is registered in ClinicalTrials.gov with Clinical Service, China as lead sponsor.

NCT NCT01328236
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01328236 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia
Lead sponsor
Clinical Service, China
Phase
Phase 2
Overall status
Unknown status
Start date
September 30, 2010
Completion date
September 30, 2015
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, plasma cell leukemia